$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000161883518000027 Filed on May 14, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.41M	$9.030M	$1.480M
YoY Change	798.43%	510.14%	-41.27%
% of Gross Profit
Research & Development	$11.83M	$11.96M	$1.982M
YoY Change	190.17%	503.38%	-39.2%
% of Gross Profit
Depreciation & Amortization	$60.00K	$70.00K	$10.00K
YoY Change	500.0%	600.0%	-50.0%
% of Gross Profit
Operating Expenses	$23.24M	$20.99M	$4.913M
YoY Change	265.56%	327.15%	-15.02%
Operating Profit	-$23.24M	-$20.99M	-$4.913M
YoY Change	265.56%	327.15%	-15.02%
Interest Expense	$30.00K	$30.00K	$10.00K
YoY Change	200.0%	200.0%	-104.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$48.07M	$353.0K
YoY Change	-100.0%	-13717.56%
Pretax Income	-$23.24M	-$69.06M	-$5.266M
YoY Change	256.91%	1211.36%	-12.67%
Income Tax	$2.000K	$0.00	$3.000K
% Of Pretax Income
Net Earnings	-$23.24M	-$69.06M	-$5.269M
YoY Change	256.94%	1210.61%	-12.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.114M	-$4.613M	-$1.309M
COMMON SHARES
Basic Shares Outstanding	17.76M shares		13.83M
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.80M	$5.000M	$9.700M
YoY Change	200.0%	-48.45%	-59.75%
Cash & Equivalents	$22.79M	$5.029M	$4.553M
Short-Term Investments
Other Short-Term Assets	$1.300M	$2.200M	$900.0K
YoY Change	160.0%	144.44%	-18.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$24.48M	$7.206M	$10.60M
YoY Change	202.16%	-32.02%	-57.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$717.0K	$783.0K	$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$977.0K	$1.003M	$100.0K
YoY Change	877.0%	903.0%	-50.0%
Total Long-Term Assets	$1.694M	$1.786M	$100.0K
YoY Change	1594.0%	1686.0%	-66.67%
TOTAL ASSETS
Total Short-Term Assets	$24.48M	$7.206M	$10.60M
Total Long-Term Assets	$1.694M	$1.786M	$100.0K
Total Assets	$26.17M	$8.992M	$10.70M
YoY Change	219.13%	-15.96%	-58.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.998M	$13.31M	$1.000M
YoY Change	1499.6%	1230.9%	-28.57%
Accrued Expenses	$11.10M	$12.59M	$700.0K
YoY Change	825.33%	1698.14%	-58.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.84M	$27.03M	$1.700M
YoY Change	1125.88%	1490.24%	-56.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$158.0K
YoY Change
Total Long-Term Liabilities	$0.00	$158.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.84M	$27.03M	$1.700M
Total Long-Term Liabilities	$0.00	$158.0K	$0.00
Total Liabilities	$20.91M	$27.28M	$1.700M
YoY Change	1130.06%	1504.94%	-75.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$399.7M	-$376.5M
YoY Change	203.54%
Common Stock	$405.0M	$358.2M
YoY Change	193.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.258M	-$18.29M	$9.000M
YoY Change
Total Liabilities & Shareholders Equity	$26.17M	$8.992M	$10.70M
YoY Change	218.61%	-15.96%	-58.04%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$23.24M	-$69.06M	-$5.269M
YoY Change	256.94%	1210.61%	-12.57%
Depreciation, Depletion And Amortization	$60.00K	$70.00K	$10.00K
YoY Change	500.0%	600.0%	-50.0%
Cash From Operating Activities	-$19.19M	-$18.14M	-$1.840M
YoY Change	788.43%	885.76%	-75.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.150M	$10.00K
YoY Change		21400.0%
Cash From Investing Activities	$0.00	$2.150M	$10.00K
YoY Change		21400.0%
FINANCING ACTIVITIES
Cash Dividend Paid		$200.0K
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	36.93M	$19.89M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-19.19M	-$18.14M	-1.840M
Cash From Investing Activities	0.000	$2.150M	10.00K
Cash From Financing Activities	36.93M	$19.89M	0.000
Net Change In Cash	17.74M	$3.897M	-1.830M
YoY Change	-921.3%	-312.95%	-86.6%
FREE CASH FLOW
Cash From Operating Activities	-$19.19M	-$18.14M	-$1.840M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	evfm	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	1400000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2018Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	14062000	USD
CY2018Q1	evfm	Weighted Average Remaining Period WeightedAverageRemainingPeriod	P1Y10M24D
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
CY2018Q1	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-19800000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8999000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13309000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12086000	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17763340	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2017Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	8789000	USD
CY2018Q1	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	9474000	USD
CY2017Q4	evfm	Accrued Deferred Offering Costs Current AccruedDeferredOfferingCostsCurrent	135000	USD
CY2018Q1	evfm	Accrued Deferred Offering Costs Current AccruedDeferredOfferingCostsCurrent	186000	USD
CY2017Q4	evfm	Accrued Directors Fees And Related Expenses Current AccruedDirectorsFeesAndRelatedExpensesCurrent	247000	USD
CY2018Q1	evfm	Accrued Directors Fees And Related Expenses Current AccruedDirectorsFeesAndRelatedExpensesCurrent	173000	USD
CY2017Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	2000000	USD
CY2018Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	2000000	USD
CY2018Q1	evfm	Deemed Contribution Upon Exchange Of Preferred Stock DeemedContributionUponExchangeOfPreferredStock	49334000	USD
CY2017Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	16000	USD
CY2018Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	392000	USD
CY2017Q1	evfm	Deferred Rent Adjustment DeferredRentAdjustment	8000	USD
CY2018Q1	evfm	Deferred Rent Adjustment DeferredRentAdjustment	186000	USD
CY2017Q1	evfm	Early Lease Termination Fees EarlyLeaseTerminationFees	55000	USD
CY2017Q1	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	0	USD
CY2018Q1	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	-47920000	USD
CY2017Q1	evfm	Loss On Issuance Of Redeemable Convertible Preferred Stock And Related Warrants Net LossOnIssuanceOfRedeemableConvertiblePreferredStockAndRelatedWarrantsNet	0	USD
CY2018Q1	evfm	Loss On Issuance Of Redeemable Convertible Preferred Stock And Related Warrants Net LossOnIssuanceOfRedeemableConvertiblePreferredStockAndRelatedWarrantsNet	47920000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Net Payments Due OperatingLeasesFutureMinimumNetPaymentsDue	1306000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Net Payments Due Current OperatingLeasesFutureMinimumNetPaymentsDueCurrent	474000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Net Payments Due In Three Years OperatingLeasesFutureMinimumNetPaymentsDueInThreeYears	171000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Net Payments Due In Two Years OperatingLeasesFutureMinimumNetPaymentsDueInTwoYears	661000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Current OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsCurrent	398000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Three Years OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInThreeYears	140000	USD
CY2018Q1	evfm	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Two Years OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInTwoYears	547000	USD
CY2014Q4	evfm	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized	0.010
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12587000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1211000	USD
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5029000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5088000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	727000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	437000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	342000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	407000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17650000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	358196000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	80000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	688000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	219000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	688000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6472660	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2410835	shares
CY2017Q4	us-gaap	Assets Assets	3952000	USD
CY2018Q1	us-gaap	Assets Assets	8992000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	2354000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	7206000	USD
CY2018Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	612000	USD
CY2018Q1	us-gaap	Cash Cash	5000000	USD
CY2017Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2018Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1900000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4553000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5598000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11487000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5088000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1701000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5598000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6399000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3897000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.62
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	11875	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2011875	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2988246	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4051137	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2082053	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17763340	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2082053	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17763340	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	81000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	114000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	92000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	48000	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	79870000	USD
CY2018Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5200000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.14
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.62
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2392000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1138000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2931000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9027000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5266000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69056000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	805000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3964000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1650000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	390000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-469000	USD
CY2018Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1479000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	574000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	31000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2015Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
CY2017Q4	us-gaap	Liabilities Liabilities	103627000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	27284000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3952000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8992000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	103347000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	27034000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-350000	USD
CY2018Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-130000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	79870000	USD
CY2017Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2018Q1	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-580000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	19885000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	250000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6157000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-69122000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	46000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2150000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6069000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18138000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-5269000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-69056000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-353000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48070000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	4913000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	20986000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4913000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20986000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2391000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	872000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	1085000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	311000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1208000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	188000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	317000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	750000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1003000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	158000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-50000	USD
CY2018Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	USD
CY2017Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2018Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	157000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	580000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	653000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1608000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2018Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	20000000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1190000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1190000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	848000	USD
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	490000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	783000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1982000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11959000	USD
CY2018Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	569000	USD
CY2017Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	535000	USD
CY2018Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	569000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-307277000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376490000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376500000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	219000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	688000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.909
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.15
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	28333	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	749305	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5300000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	458586	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6645	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3136030	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	200000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2017Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	121315000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5226000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-289546000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-18292000	USD
CY2018Q1	us-gaap	Stockholders Equity Change In Reporting Entity StockholdersEquityChangeInReportingEntity	1946000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	166.7000
CY2018Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	223000	USD
CY2017Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	888000	USD
CY2018Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	66000	USD
CY2018Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	14100000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1959904	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14974458	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions in excess of federally insured limits. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On an ongoing basis, Management evaluates its estimates related to, but not limited to, the useful lives of property and equipment, the recoverability of long-lived assets, preclinical and clinical trial accruals, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants issued to Invesco Asset Managementto (the Invesco Warrants), assumptions used in estimating the fair value of stock-based compensation expense and other contingencies. The Company’s assumptions regarding the measurement of the Series D 2X liquidation preference and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#s99ED32E54B6F192208488D25BEA19A8F"><font style="font-family:inherit;font-size:10pt;">Note 5 — Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;"> and </font><a style="font-family:inherit;font-size:10pt;" href="#s99ED32E54B6F192208488D25BEA19A8F"><font style="font-family:inherit;font-size:10pt;">Note 10 — Stock-based Compensation,</font></a><font style="font-family:inherit;font-size:10pt;"> respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-18-000027-index-headers.html	Edgar Link	pending
0001618835-18-000027-index.html	Edgar Link	pending
0001618835-18-000027.txt	Edgar Link	pending
0001618835-18-000027-xbrl.zip	Edgar Link	pending
evfm-20180331.xml	Edgar Link	completed
evfm-20180331.xsd	Edgar Link	pending
evfm-20180331_cal.xml	Edgar Link	unprocessable
evfm-20180331_def.xml	Edgar Link	unprocessable
evfm-20180331_lab.xml	Edgar Link	unprocessable
evfm-20180331_pre.xml	Edgar Link	unprocessable
evfm-3312016ex312.htm	Edgar Link	pending
evfm-331201810xq.htm	Edgar Link	pending
evfm-3312018ex311.htm	Edgar Link	pending
evfm-3312018ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image1a01.jpg	Edgar Link	pending
image2.jpg	Edgar Link	pending
image3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2018 Q2 Form 10-Q Financial Statement

#000161883518000027 Filed on May 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2018 Q2 Form 10-Q Financial Statement

#000161883518000027 Filed on May 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm